Midostaurin and its Impurities
Midostaurin, sold under the brand name Rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia, myelodysplastic syndrome and advanced systemic mastocytosis.Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients. Reference standards of Midostaurin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
N-((5R,6S,7S,9R)-6-Methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
N-((5R,6S,7S,9R)-6-Methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181003
CAS :
666838-30-8
Molecular Formula : C35H30N4O4
Molecular Weight : 570.65
N-((5S,6R,7R,9S)-6-Methoxy-5-methyl-14,16-dioxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
N-((5S,6R,7R,9S)-6-Methoxy-5-methyl-14,16-dioxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181007
CAS :
154589-96-5
Molecular Formula : C35H28N4O5
Molecular Weight : 584.63
N-((5S,6R,7R,9R,16S)-16-Hydroxy-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
N-((5S,6R,7R,9R,16S)-16-Hydroxy-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-7-yl)-N-methylbenzamide
Catalogue No.:PA 13 2181009
CAS :
945260-14-0
Molecular Formula : C35H30N4O5
Molecular Weight : 586.65
